Alnylam Pharmaceuticals
ALNY
ALNY
441 hedge funds and large institutions have $18.6B invested in Alnylam Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 154 increasing their positions, 148 reducing their positions, and 56 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
more ownership
Funds ownership: →
4% more repeat investments, than reductions
Existing positions increased: 154 | Existing positions reduced: 148
0% less capital invested
Capital invested by funds: $18.6B → $18.6B (-$35M)
28% less call options, than puts
Call options by funds: $143M | Put options by funds: $199M
Holders
441
Holding in Top 10
8
Calls
$143M
Puts
$199M
Top Buyers
| 1 | +$928M | |
| 2 | +$101M | |
| 3 | +$75.7M | |
| 4 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$42.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$42.3M |
Top Sellers
| 1 | -$309M | |
| 2 | -$168M | |
| 3 | -$166M | |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$77.9M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$62.7M |